BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 10888615)

  • 1. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
    Ly A; Stamatatos L
    J Virol; 2000 Aug; 74(15):6769-76. PubMed ID: 10888615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
    McCaffrey RA; Saunders C; Hensel M; Stamatatos L
    J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.
    Sagar M; Wu X; Lee S; Overbaugh J
    J Virol; 2006 Oct; 80(19):9586-98. PubMed ID: 16973562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
    Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
    PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
    Means RE; Matthews T; Hoxie JA; Malim MH; Kodama T; Desrosiers RC
    J Virol; 2001 Apr; 75(8):3903-15. PubMed ID: 11264379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
    Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.
    Saunders CJ; McCaffrey RA; Zharkikh I; Kraft Z; Malenbaum SE; Burke B; Cheng-Mayer C; Stamatatos L
    J Virol; 2005 Jul; 79(14):9069-80. PubMed ID: 15994801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of antipeptide antibodies produced against V2 and V3 regions of the external envelope of human immunodeficiency virus type 2.
    Babas T; Benichou S; Guetard D; Montagnier L; Bahraoui E
    Mol Immunol; 1994 Apr; 31(5):361-9. PubMed ID: 8152439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.
    Painter SL; Biek R; Holley DC; Poss M
    J Virol; 2003 Aug; 77(15):8448-61. PubMed ID: 12857914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
    Martín J; LaBranche CC; González-Scarano F
    J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity.
    Foda M; Harada S; Maeda Y
    Microbiol Immunol; 2001; 45(7):521-30. PubMed ID: 11529558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism.
    Ogert RA; Lee MK; Ross W; Buckler-White A; Martin MA; Cho MW
    J Virol; 2001 Jul; 75(13):5998-6006. PubMed ID: 11390601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.
    Maeda Y; Foda M; Matsushita S; Harada S
    J Virol; 2000 Feb; 74(4):1787-93. PubMed ID: 10644351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
    Vijh-Warrier S; Pinter A; Honnen WJ; Tilley SA
    J Virol; 1996 Jul; 70(7):4466-73. PubMed ID: 8676471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.
    Kato K; Sato H; Takebe Y
    J Virol; 1999 Jul; 73(7):5520-6. PubMed ID: 10364300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.
    Parrish NF; Wilen CB; Banks LB; Iyer SS; Pfaff JM; Salazar-Gonzalez JF; Salazar MG; Decker JM; Parrish EH; Berg A; Hopper J; Hora B; Kumar A; Mahlokozera T; Yuan S; Coleman C; Vermeulen M; Ding H; Ochsenbauer C; Tilton JC; Permar SR; Kappes JC; Betts MR; Busch MP; Gao F; Montefiori D; Haynes BF; Shaw GM; Hahn BH; Doms RW
    PLoS Pathog; 2012; 8(5):e1002686. PubMed ID: 22693444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops.
    Kolchinsky P; Kiprilov E; Bartley P; Rubinstein R; Sodroski J
    J Virol; 2001 Apr; 75(7):3435-43. PubMed ID: 11238869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.